In support of its effects on global RNAPII transcription, SNS-032 treatment led to a decrease in phosphorylated Ser2 and Ser5 of RNAPII CTD and decreased expression of antiapoptotic proteins Mcl-1 and XIAP in a variety of cancers, such as multiple myeloma [84], acute myeloid leukemia (AML) [85], neuroblastoma [86] and breast cancer [47]. This evidence concerns the gene MCL1 and plasma cell myeloma.